Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Operating Cash Flow

Cash generated by the company's core business operations during the period.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $118.92M (cash outflow) rose 6.7% year over year, ahead of the -5.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 23.6% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • Operating cash flow amounted to 690.3% of revenue in FY2025, down 377.8 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +6.7% holds above the trailing-twelve-month pace of -5.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$118.92M+23.6% QoQ
Last fiscal yearDec 2025
-$372.98M-4.3% YoY
LTMMar 2026
-$380.41M-5.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.7%——
1 year-4.3%——
3-year CAGR+6.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(372.98M) USD
Year-over-year change
+4.3%

Operating Cash Flow vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 operating cash flow of $380.41M is the 3rd largest of the 7 companies compared; the peer median is $110.22M.
  • Its year-over-year change of -5.2% is the 5th highest of 7, against a peer median of +21.3%.
  • Operating cash flow amounts to 576.0% of revenue for AGIO, versus a peer median of 38.3%.
AGIO Competitors Peer median
Operating Cash Flow for AGIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$496.53M +27.3%+7.0%74.2%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$456.03M -5169.8%—73.8%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$380.41M -5.2%+6.4%576.0%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$359.87M +2039.9%—38.3%
IRONDisc Medicine, Inc.LTM Sep 2026$189.94M +15.3%+62.2%—
PHARPharming Group N.V.LTM Mar 2026$50.77M +733.1%+30.6%13.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$30.5M -104.3%—3.0%
Peer median (excluding AGIO) $110.22M+21.3%+30.6%38.3%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(356.51M)(231.8M)(352.09M)673.73M(412.78M)
Depreciation & Amortization9.24M8.56M6.62M5.65M5.18M
Deferred Income Tax00000
Stock-Based Compensation53.51M49.3M44.77M42.85M52.55M
Change in Working Capital(36.82M)(16.43M)(19.06M)(19.77M)(33.04M)
Accounts Receivables(4.38M)(2.21M)(604K)(1.3M)(6.47M)
Inventory0(8.49M)(10.58M)(8.54M)(5.3M)
Accounts Payables1.86M3.44M(8.73M)6.6M1.75M
Other Working Capital(34.31M)(9.17M)864K(16.53M)(23.02M)
Other Non-Cash Items(76.74M)(119.1M)23.69M(1.09B)15.12M
Operating Cash Flow(407.32M)(309.48M)(296.06M)(389.84M)(372.98M)
Capital Expenditures(5.74M)(4.88M)(999K)(1.69M)(4.32M)
Acquisitions (Net)0132.75M040K0
Purchases of Investments(1.38B)(1.03B)(417.93M)(1.54B)(641.76M)
Sales of Investments829.8M1.15B674.68M818.38M1.03B
Other Investing Activities1.8B0(16.18M)1.09B(10M)
Investing Cash Flow1.25B243.26M239.58M363.44M377.18M
Debt Repayment(578K)(331K)000
Common Stock Issued02.68M5.43M14.44M8.68M
Common Stock Repurchased(802.49M)0000
Dividends Paid00000
Other Financing Activities37.3M0000
Financing Cash Flow(765.77M)2.35M5.43M14.44M8.68M
Effect of Forex Changes00000
Net Change in Cash75.69M(63.87M)(51.05M)(11.96M)12.88M
Free Cash Flow(413.06M)(314.36M)(297.06M)(391.53M)(377.29M)

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.